Physician profile
Alok Sachdeva
NPI 1750504262
$10,092.09
in general payments reported to CMS, 2019-2025
32 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $737 · 2021: $1,730 · 2022: $1,871 · 2023: $2,015 · 2024: $1,174 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299 · Education: $33.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.90 |
| Education | $33.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,539.63 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $1,961.36 | 2019-2025 | |
| Amgen INC. | $1,280.92 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $356.15 | 2020-2023 | |
| Ucb, INC. | $311.32 | 2019-2025 | Cimzia, Bimzelx |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.63 | 2019-2023 | Ofev |
| Horizon Therapeutics Plc | $158.05 | 2019 | |
| United Therapeutics Corporation | $125.00 | 2025 | |
| Resmed Corp | $101.29 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $92.59 | 2022-2025 | Opsumit, Uptravi |
| Xeris Pharmaceuticals, INC. | $89.45 | 2024-2025 | Gvoke Hypopen |
| Harmony Biosciences LLC | $82.88 | 2023-2024 | Wakix |
| Glaxosmithkline, LLC. | $68.31 | 2019-2023 | Benlysta |
| Janssen Biotech, INC. | $58.72 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $58.30 | 2023-2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $52.99 | 2021 | |
| Novo Nordisk INC | $52.27 | 2024-2025 | Rybelsus, Ozempic |
| Beta Bionics, INC. | $40.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $34.70 | 2019-2023 | |
| Lilly USA, LLC | $34.54 | 2021-2025 | Zepbound, Mounjaro |
| Aurinia Pharma U.S., INC. | $32.23 | 2023 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $24.99 | 2023 | Saphnelo |
| Baxter Healthcare | $24.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Antares Pharma, INC. | $20.28 | 2019 | |
| Sobi, INC | $19.25 | 2024 | |
| Embecta Corp. | $17.53 | 2024 | |
| Genentech USA, INC. | $17.47 | 2023 | Actemra |
| Mannkind Corporation | $16.24 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.05 | 2019 | |
| Medexus Pharma, INC. | $13.48 | 2020 | |
| Radius Health, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.